Al-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases

Clinical trials in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis) require histologic scoring for assessment of inclusion criteria and endpoints. However, variability in interpretation has impacted clinical trial outcomes. We developed an artificial intelligence-based measurement (AIM) tool for scoring MASH histology (AIM-MASH). AIM-MASH predictions for MASH Clinical Research Network necroinflammation grades and fibrosis stages were reproducible (κ = 1) and aligned with expert pathologist consensus scores (κ = 0.62–0.74). The AIM-MASH versus consensus agreements were comparable to average pathologists for MASH Clinical Research Network scores (82% versus 81%) and fibrosis (97% versus 96%). Continuous scores produced by AIM-MASH for key histological features of MASH correlated with mean pathologist scores and noninvasive biomarkers and strongly predicted progression-free survival in patients with stage 3 (P < 0.0001) and stage 4 (P = 0.03) fibrosis. In a retrospective analysis of the ATLAS trial (NCT03449446), responders receiving study treatment showed a greater continuous change in fibrosis compared with placebo (P = 0.02). Overall, these results suggest that AIM-MASH may assist pathologists in histologic review of MASH clinical trials, reducing inter-rater variability on trial outcomes and offering a more sensitive and reproducible measure of patient responses.

Janani S Iyer, Dinkar Juyal, Quang Le, Zahil Shanis, Harsha Pokkalla, Maryam Pouryahya, Aryan Pedawi, S Adam Stanford-Moore, Charles Biddle-Snead, Oscar Carrasco-Zevallos, Mary Lin, Robert Egger, Sara Hoffman, Hunter Elliott, Kenneth Leidal, Robert P Myers, Chuhan Chung, Andrew N Billin, Timothy R Watkins, Scott D Patterson, Murray Resnick, Katy Wack, Jon Glickman, Alastair D Burt, Rohit Loomba, Arun J Sanyal, Ben Glass, Michael C Montalto, Amaro Taylor-Weiner, Ilan Wapinski, Andrew H Beck